Keeping the pressure down: optimizing our approaches to managing pulmonary arterial hypertension (PAH) - CME

CME

Title: Keeping the pressure down: optimizing our approaches to managing pulmonary arterial hypertension (PAH)

Description: Pulmonary hypertension (PH) comprises five etiologic groups; Group I, pulmonary arterial hypertension (PAH), is a precapillary entity defined hemodynamically by right‑heart catheterization: mean pulmonary artery pressure >20 mm Hg, pulmonary artery wedge pressure ≤15 mm Hg, and pulmonary vascular resistance >=3 Wood units. PAH is uncommon but consequential; estimates place U.S. prevalence near 10.6 per million, with contemporary data showing rarity yet meaningful population burden. Sex differences are notable—women predominate, while men may experience more severe trajectories—underscoring the need for sex‑aware assessment. Multinational reviews suggest incidence and prevalence remain non‑trivial, with enduring morbidity and mortality despite therapeutic gains.

Target Audience: HCPs including but not limited to: pulmonology, cardiology, and primary care; physician assistants, nurse practitioners, and pharmacists who practice in the aforementioned areas of specialty; and any other healthcare professionals with an interest in or who clinically encounter patients with PH.

Learning Objectives

Recall contemporary hemodynamic definition and PH classification.
Describe appropriate first-line testing and structured risk tools for PAH.
Choose evidence-based, risk-aligned therapy to treat PAH.
Explain how vascular and right ventricular remodeling pathways drive disease progression and inform the rationale for multi-pathway and emerging therapies in PAH.
Discuss challenges to the optimal management of PAH and the value of risk reassessment, early referral to PH centers, and multidisciplinary coordination.

Disclosures and Disclaimers: As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Accredited Providers

Commercial Support

Credit Information

Credit Type	Units / Unit Type	Board
AMA PRA Category 1 Credit	1 Credits	ACCME- Accreditation Council for Continuing Medical Education